(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, ...

BWX Technologies reached a record high, leading nuclear-related stocks on reports the US Secretary of Transportation is set ...

Politico reported late Monday that Transportation Secretary and interim NASA head Duffy will announce this week expedited ...

In the VISION study reported at ASCO last year, Pluvicto given on top of standard care reduced the risk of death by 38% compared to standard care alone in men with PSMA+ mCRPC who had progressed ...

Average selling prices of Illuccix will likely decrease when its transitional pass-through payment status expires in 2025.

If approved, it would compete with Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which is on track to breach the $1 billion-a-year sales threshold in 2024.

Bildnachweis: ITM. The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory ...

Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted ...